@article{Mazzucchelli_Frustaci_Deodato_Cairoli_Tedeschi_2018, title={WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE}, volume={10}, url={https://www.mjhid.org/mjhid/article/view/3183}, DOI={10.4084/mjhid.2018.004}, abstractNote={<p lang="en-GB" align="justify"><span style="font-family: Arial, serif;">Waldenstrom Macroglobulinemia is a rare lymphoproliferative disorder with distinctive clinical features.</span></p><p lang="en-GB" align="justify"><span style="font-family: Arial, serif;">Diagnostic and prognostic charactrization in WM significantly changed with the discovery of two molecular markers: MYD88 and CXCR4. Mutational status of these latter influences both clinical presentation and prognosis and demonstrated therapeutic implications.</span></p><p lang="zxx" align="justify"><span style="font-family: Arial, serif;"><span lang="en-GB">Treatment choice in Waldemstrom disease is strictly guided by </span></span><span style="font-family: Arial, serif;"><span lang="en-US">patients age and characteristics, specific goals of therapy, necessity for rapid disease control, risk of treatment-related neuropathy, disease characteristics, risk of immunosuppression or secondary malignancies and potential for future autologous stem cell transplantation.</span></span></p><p lang="en-US" align="justify"><span style="font-family: Arial, serif;">Therapeutic landscape has expanded during the last years and the approval of ibrutinib, the first drug approved for Waldenstrom Macroglobulinemia, represents an important step forward for a better management of the disease. </span></p>}, number={1}, journal={Mediterranean Journal of Hematology and Infectious Diseases}, author={Mazzucchelli, Maddalena and Frustaci, Anna Maria and Deodato, Marina and Cairoli, Roberto and Tedeschi, Alessandra}, year={2018}, month={Jan.}, pages={e2018004} }